Tables

Tables in the 10-Q of CLOROX CO /DE/

39 tables with numbers, filed Nov 3, 2025. Each one downloads as an Excel file or a CSV (numbers are stored as numbers), with the filing's address in the last row. Only the layout is tidied (a "$" or ")" in a cell of its own is joined to its number); no value is changed. Open the filing on sec.gov ↗

	Page
PART I - FINANCIAL INFORMATION	3
Item 1. Financial Statements	3
Condensed Consolidated Statements of Earnings	3
Condensed Consolidated Statements of Comprehensive Income	4
Condensed Consolidated Balance Sheets	5
Condensed Consolidated Statements of Cash Flows	6
Notes to Condensed Consolidated Financial Statements	7

	Three months ended
	9/30/2025	9/30/2024
Net sales	$1,429		$1,762
Cost of products sold	833		955
Gross profit	596		807
Selling and administrative expenses	277		281
Advertising costs	166		201
Research and development costs	28		31

	9/30/2025	6/30/2025
	(Unaudited)
ASSETS
Current assets
Cash and cash equivalents	$166		$167
Receivables, net	703		821
Inventories, net	577		523
Prepaid expenses and other current assets	249		97

	9/30/2025	6/30/2025
Finished goods	$500		$447
Raw materials and packaging	149		141
Work in process	18		15
LIFO allowances	(90)		(80)
Total inventories, net	$577		$523

	Gains (losses) recognized in Other comprehensive (loss) income
	Three months ended
	9/30/2025	9/30/2024
Commodity purchase derivative contracts	$—		$(3)
Foreign exchange derivative contracts	—		(1)
Total	$—		$(4)

	Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings	Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
		Three months ended
		9/30/2025	9/30/2024
Commodity purchase derivative contracts	Cost of products sold	$2		$(1)
Foreign exchange derivative contracts	Cost of products sold	(1)		—
Interest rate derivative contracts	Interest expense	3		3
Total		$4		$2

			9/30/2025	6/30/2025
	Balance sheet classification	Fair value hierarchy level	Carrying Amount	Estimated Fair Value		Carrying Amount	Estimated Fair Value
Assets
Commodity purchase futures contracts	Prepaid expenses and other current assets	1	$1		$1		$3	$3
Commodity purchase futures contracts	Other assets	1	—		—		1	1
Foreign exchange forward contracts	Prepaid expenses and other current assets	2	1		1		—	—
			$2		$2		$4	$4
Liabilities

	Three months ended September 30
(Dollars in millions except per share data; shares in thousands)	Common stock		Additional paid-in capital		Retained earnings		Treasury stock		Accumulated other comprehensive net (loss) income		Noncontrolling interests	Total stockholders’ equity
Amount		Shares				Amount		Shares
Balance as of June 30, 2024	$131			130,741			$1,288			$250		$(1,186)	(6,540)	$(155)	$164	$492
Net earnings	—			—			—			99		—	—	—	4	103
Other comprehensive income (loss)	—			—			—			—		—	—	8	—	8
Dividends to Clorox stockholders ($2.44 per share declared)	—			—			—			(305)		—	—	—	—	(305)
Dividends to noncontrolling interests	—			—			—			—		—	—	—	(4)	(4)

	Three months ended September 30
	Foreign currency translation adjustments	Net unrealized gains (losses) on derivatives		Pension and postretirement benefit adjustments	Accumulated other comprehensive net (loss) income
Balance as of June 30, 2024	$(239)		$85		$(1)	$(155)
Other comprehensive (loss) income before reclassifications	14		(4)		—	10
Amounts reclassified from Accumulated other comprehensive net (loss) income	—		(2)		—	(2)
Income tax benefit (expense)	—		—		—	—
Net current period other comprehensive (loss) income	14		(6)		—	8
Balance as of September 30, 2024	$(225)		$79		$(1)	$(147)

	Segment adjusted earnings (losses) before interest and income taxes
	Three months ended September 30, 2025
	Health and Wellness	Household		Lifestyle	International	Total
Net sales	$565		$362		$245		$253
Cost of products sold	291		246		126		165
Other segment items (1)	150		89		81		69
Segment adjusted EBIT	$124		$27		$38		$19	$208
Corporate and Other						(48)

	Three months ended
	9/30/2025	9/30/2024
Basic	122,629	123,795
Dilutive effect of stock options and other	389	882
Diluted	123,018	124,677
Antidilutive stock options and other	3,355	2,937

	Net sales
	Three months ended
	9/30/2025	9/30/2024
Cleaning	35%		34%
Professional Products	5		6
Health and Wellness	40%		40%
Bags and Wraps	11		11
Cat Litter	9		9

	Three months ended September 30, 2025
	Percentage change versus the year-ago period
	Reported (GAAP) Net Sales Growth / (Decrease)	Reported Volume		Acquisitions & Divestitures (1)	Foreign Exchange Impact	Price/Mix/ Other (2)	Organic Sales Growth / (Decrease) (Non-GAAP) (3)	Organic Volume (4)
Health and Wellness	(19)%		(16)%			—%		—%	(3)%	(19)%	(16)%
Household	(19)		(18)			—		—	(1)	(19)	(18)
Lifestyle	(23)		(22)			—		—	(1)	(23)	(22)
International	(2)		(2)			—		—	—	(2)	(2)
Total Company (4)(5)	(19)%		(18)%			(2)%		—%	(1)%	(17)%	(15)%

	Three months ended
	9/30/2025	9/30/2024
Net cash provided by operations	$93		$221
Net cash (used for) provided by investing activities	(34)		89
Net cash used for financing activities	(59)		(237)

	Segment adjusted earnings (losses) before interest and income taxes
	Three months ended September 30, 2024
	Health and Wellness	Household		Lifestyle	International	Total
Net sales	$698		$447		$320		$259
Cost of products sold	322		289		157		158
Other segment items (1)	141		98		97		66
Segment adjusted EBIT	$235		$60		$66		$35	$396
Corporate and Other						(64)

	Three months ended
					% of Net Sales
	9/30/2025	9/30/2024		% Change	9/30/2025	9/30/2024
Selling and administrative expenses	$277		$281		(1)%		19.4%	15.9%
Advertising costs	166		201		(17)		11.6	11.4
Research and development costs	28		31		(10)		2.0	1.8

	Segment adjusted EBIT (1)
	Three months ended
	9/30/2025	9/30/2024
Health and Wellness	$124		$235
Household	27	60
Lifestyle	38	66
International	19	35
Reportable segment total	$208		$396

	Reconciliation of earnings before income taxes to adjusted EBIT
	Three months ended
	9/30/2025	9/30/2024
Earnings before income taxes	$107		$177
Interest income	(2)		(3)
Interest expense	23		21
Loss on divestiture (1)	—		118
Cyberattack costs, net of insurance recoveries (2)	—		(10)

	[a]	[b]		[c]	[d]
Period	Total Number ofShares Purchased	Average Price Paidper Share (2)		Total Number ofShares Purchased asPart of PubliclyAnnounced Plans orPrograms (1)	Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs
July 1 to 31, 2025	395,766		$126.34		395,766	$993 million
August 1 to 31, 2025	652,257		121.25		652,257	$953 million
September 1 to 30, 2025	—		—		—	$953 million
Total	1,048,023		$123.22		1,048,023

Exhibit Number	Exhibit Description
10.1	Form of Restricted Stock Unit Award Agreement under the Company’s 2005 Stock Incentive Plan (Annual Grant) for awards made in 2025.
10.2	Form of Restricted Stock Unit Award Agreement under the Company’s 2005 Stock Incentive Plan (Off-Cycle Grant) for awards made in 2025.
10.3	Form of Performance Share Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2025
31.1	Certification by the Chief Executive Officer of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification by the Chief Financial Officer of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32	Certification by the Chief Executive Officer and Chief Financial Officer of the Company Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.SCH	XBRL Taxonomy Extension Schema Document.

Tables in the 10-Q of CLOROX CO /DE/

Table 1 after “TABLE OF CONTENTS”

Table 2 after “(Dollars in millions, except per share data)”

Table 3 after “(Dollars in millions)”

Table 4 after “(Dollars in millions, except per share data)”

Table 5 after “(Dollars in millions)”

Table 6 after “Inventories, net consisted of the following as of:”

Table 7 after “The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follow”

Table 8 after “The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follow”

Table 9 after “The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:”

Table 10 after “The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabil”

Table 11 after “The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to t”

Table 12 after “The major components of Other (income) expense, net were:”

Table 13 after “Changes in the components of Stockholders’ equity were as follows for the periods indicated:”

Table 14 after “Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:”

Table 15 after “Net sales by segment and a reconciliation to the Company’s consolidated net sales for the three months ended September 30:”

Table 16 after “Segment adjusted EBIT, including the significant segment expense provided to the CODM, and a reconciliation to earnings before income taxes ”

Table 17 after “NOTE 12. SEGMENT RESULTS (Continued)”

Table 18 after “Certain other segment disclosures were as follows:”

Table 19 after “The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the ”

Table 20 after “CONSOLIDATED RESULTS”

Table 21 after “CONSOLIDATED RESULTS”

Table 22 after “in the current period decreased by 19% and 18%, respectively, driven by lower shipments in the current period following the incremental ship”

Table 23 after “Expenses”

Table 24 after “Loss on divestiture, interest expense, other (income) expense, net and the effective tax rate on earnings”

Table 25 after “Diluted net earnings per share”

Table 26 after “The following presents the results of the Company’s reportable segments and Corporate and Other. See notes to condensed consolidated financi”

Table 27 after “The following presents the results of the Company’s reportable segments and Corporate and Other. See notes to condensed consolidated financi”

Table 28 after “Health and Wellness”

Table 29 after “Household”

Table 30 after “Lifestyle”

Table 31 after “International”

Table 32 after “Corporate and Other includes certain non-allocated administrative and other costs, various other non-operating income and expenses, as well ”

Table 33 after “The Company’s financial condition and liquidity remained strong as of September 30, 2025. The following table summarizes cash activities:”

Table 34 after “Dividends per share declared and total dividends paid to Clorox stockholders were as follows for the periods indicated:”

Table 35 after “is the ratio of adjusted EBIT to net sales.”

Table 36 after “During the three months ended September 30, 2025 and 2024, the Company incurred approximately $32 and $29, respectively, of operating expens”

Table 37 after “The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the m”

Table 38 after “The following table sets forth the purchases of the Company’s securities by the Company and any affiliated purchasers within the meaning of ”

Table 39 after “EXHIBIT INDEX”